February 21, 2025

Novel Menin Inhibitors Show Safety and Activity in Several Clinical Trials

The recently approved menin inhibitor revumenib is poised to improve the treatment of acute leukemia, specifically for disease with a KMT2A rearrangement. Promising results for other novel menin inhib...

The ASCO Post

February 21, 2025

3 things you missed in government this week

ADA News is providing a roundup of three happenings in government that you may have missed this week.

ADA News

February 21, 2025

Study Links Stress to Immune Changes in Breast Cancer

New research shows chronic stressors like perceived stress, inadequate social support, racial discrimination, and neighborhood deprivation are associated with deleterious changes to systemic and tumor immunity in breast cancer patients, with more pronounced effects in Black women.

Conexiant

February 21, 2025

Environmental vs. Genetic Risk in Aging and Mortality

Researchers quantify the exposome's greater impact on aging and mortality risk compared with genetic predisposition, identifying 25 key environmental risk factors.

Conexiant

February 21, 2025

Early-Stage Classic Hodgkin Lymphoma

The recent history of classic Hodgkin lymphoma (cHL) clinical research and therapy has focused on therapy de-escalation while maintaining cure rates to reduce toxicity. Therapy adaptation with PET sca...

The ASCO Post

February 21, 2025

AAN: Limited Benefits Found for Epidural Steroid Injections

New systematic review from the American Academy of Neurology finds epidural steroid injections offer modest short-term benefits but limited long-term efficacy for treating spinal pain conditions, with varying results across different applications.

Conexiant

February 21, 2025

How Telehealth Is Broadening Access to Early Palliative Care and Improving Outcomes for Patients With Advanced Lung Cancer

Although national guidelines, including ASCO’s palliative care guideline,1 call for the early integration of palliative and oncology care for patients with advanced cancer, only 36% of those with a ve...

The ASCO Post

February 21, 2025

Filgotinib Shows Long-Term Safety in RA Patients

Filgotinib was well-tolerated over 8 years in rheumatoid arthritis patients, with low incidences of serious adverse events.

Conexiant

February 21, 2025

FDA Approves First Companion Diagnostic to Identify Patients With Metastatic Breast Cancer Eligible for T-DXd

The FDA has approved a label expansion for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who may be e...

The ASCO Post